<DOC>
	<DOCNO>NCT01784120</DOCNO>
	<brief_summary>To evaluate efficacy toxicity doxorubicin/Genexol-PM metastatic breast cancer 1 . Primary Purpose : response rate 2 . Secondary purpose : toxicity , progression-free survival , overall survival</brief_summary>
	<brief_title>A Phase II Trial Doxorubicin Genexol-PM Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>18 year age old adult woman Instrumentation measurable lesion histologically confirm advanced ( recurrent metastatic ) breast cancer ECOG 02 Advanced breast cancer past , patient receive chemotherapy Recurrence adjuvant chemotherapy adjuvant chemotherapy past 6 month patient life expectancy 3 month Agree write party participate clinical trial patient immunohistochemical stain 3 + FISH positive antiHER 2 therapy patient Severe infection require antibiotic therapy Clinically significant heart disease Pregnant lactate woman Uncontrolled symptoms central nervous system ( CNS ) metastases Patients diagnose malignant tumor organ</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>genexol-PM</keyword>
	<keyword>paclitaxel</keyword>
</DOC>